Cardiovascular disease and risk in COPD: a state of the art review

Research output: Contribution to journalReviewResearchpeer-review

Standard

Cardiovascular disease and risk in COPD : a state of the art review. / Polman, Ricardo; Hurst, John R.; Uysal, Omer Faruk; Mandal, Swapna; Linz, Dominik; Simons, Sami.

In: Expert Review of Cardiovascular Therapy, Vol. 22, No. 4-5, 2024.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Polman, R, Hurst, JR, Uysal, OF, Mandal, S, Linz, D & Simons, S 2024, 'Cardiovascular disease and risk in COPD: a state of the art review', Expert Review of Cardiovascular Therapy, vol. 22, no. 4-5. https://doi.org/10.1080/14779072.2024.2333786

APA

Polman, R., Hurst, J. R., Uysal, O. F., Mandal, S., Linz, D., & Simons, S. (2024). Cardiovascular disease and risk in COPD: a state of the art review. Expert Review of Cardiovascular Therapy, 22(4-5). https://doi.org/10.1080/14779072.2024.2333786

Vancouver

Polman R, Hurst JR, Uysal OF, Mandal S, Linz D, Simons S. Cardiovascular disease and risk in COPD: a state of the art review. Expert Review of Cardiovascular Therapy. 2024;22(4-5). https://doi.org/10.1080/14779072.2024.2333786

Author

Polman, Ricardo ; Hurst, John R. ; Uysal, Omer Faruk ; Mandal, Swapna ; Linz, Dominik ; Simons, Sami. / Cardiovascular disease and risk in COPD : a state of the art review. In: Expert Review of Cardiovascular Therapy. 2024 ; Vol. 22, No. 4-5.

Bibtex

@article{95b812c42ad140d3921f3896c129c8c8,
title = "Cardiovascular disease and risk in COPD: a state of the art review",
abstract = "Introduction: Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) commonly co-exist. Outcomes of people living with both conditions are poor in terms of symptom burden, receiving evidence-based treatment and mortality. Increased understanding of the underlying mechanisms may help to identify treatments to relieve this disease burden. This narrative review covers the overlap of COPD and CVD with a focus on clinical presentation, mechanisms, and interventions. Literature up to December 2023 are cited. Areas Covered: 1. What is COPD 2. The co-existence of COPD and cardiovascular disease 3. Mechanisms of cardiovascular disease in COPD. 4. Populations with COPD are at risk of CVD 5. Complexity in the co-diagnosis of COPD in those with cardiovascular disease. 6. Therapy for COPD and implications for cardiovascular events and risk. 7. Cardiovascular risk and exacerbations of COPD. 8. Pro-active identification and management of CV risk in COPD. Expert Opinion: The prospective identification of co-morbid COPD in CVD patients and of CVD and CV risk in people with COPD is crucial for optimizing clinical outcomes. This includes the identification of novel treatment targets and the design of clinical trials specifically designed to reduce the cardiovascular burden and mortality associated with COPD. Databases searched: Pubmed, 2006–2023.",
keywords = "arrhythmia, cardiovascular disease, cardiovascular risk, COPD, exacerbations, therapeutics",
author = "Ricardo Polman and Hurst, {John R.} and Uysal, {Omer Faruk} and Swapna Mandal and Dominik Linz and Sami Simons",
note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2024",
doi = "10.1080/14779072.2024.2333786",
language = "English",
volume = "22",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Taylor & Francis",
number = "4-5",

}

RIS

TY - JOUR

T1 - Cardiovascular disease and risk in COPD

T2 - a state of the art review

AU - Polman, Ricardo

AU - Hurst, John R.

AU - Uysal, Omer Faruk

AU - Mandal, Swapna

AU - Linz, Dominik

AU - Simons, Sami

N1 - Publisher Copyright: © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2024

Y1 - 2024

N2 - Introduction: Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) commonly co-exist. Outcomes of people living with both conditions are poor in terms of symptom burden, receiving evidence-based treatment and mortality. Increased understanding of the underlying mechanisms may help to identify treatments to relieve this disease burden. This narrative review covers the overlap of COPD and CVD with a focus on clinical presentation, mechanisms, and interventions. Literature up to December 2023 are cited. Areas Covered: 1. What is COPD 2. The co-existence of COPD and cardiovascular disease 3. Mechanisms of cardiovascular disease in COPD. 4. Populations with COPD are at risk of CVD 5. Complexity in the co-diagnosis of COPD in those with cardiovascular disease. 6. Therapy for COPD and implications for cardiovascular events and risk. 7. Cardiovascular risk and exacerbations of COPD. 8. Pro-active identification and management of CV risk in COPD. Expert Opinion: The prospective identification of co-morbid COPD in CVD patients and of CVD and CV risk in people with COPD is crucial for optimizing clinical outcomes. This includes the identification of novel treatment targets and the design of clinical trials specifically designed to reduce the cardiovascular burden and mortality associated with COPD. Databases searched: Pubmed, 2006–2023.

AB - Introduction: Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) commonly co-exist. Outcomes of people living with both conditions are poor in terms of symptom burden, receiving evidence-based treatment and mortality. Increased understanding of the underlying mechanisms may help to identify treatments to relieve this disease burden. This narrative review covers the overlap of COPD and CVD with a focus on clinical presentation, mechanisms, and interventions. Literature up to December 2023 are cited. Areas Covered: 1. What is COPD 2. The co-existence of COPD and cardiovascular disease 3. Mechanisms of cardiovascular disease in COPD. 4. Populations with COPD are at risk of CVD 5. Complexity in the co-diagnosis of COPD in those with cardiovascular disease. 6. Therapy for COPD and implications for cardiovascular events and risk. 7. Cardiovascular risk and exacerbations of COPD. 8. Pro-active identification and management of CV risk in COPD. Expert Opinion: The prospective identification of co-morbid COPD in CVD patients and of CVD and CV risk in people with COPD is crucial for optimizing clinical outcomes. This includes the identification of novel treatment targets and the design of clinical trials specifically designed to reduce the cardiovascular burden and mortality associated with COPD. Databases searched: Pubmed, 2006–2023.

KW - arrhythmia

KW - cardiovascular disease

KW - cardiovascular risk

KW - COPD

KW - exacerbations

KW - therapeutics

U2 - 10.1080/14779072.2024.2333786

DO - 10.1080/14779072.2024.2333786

M3 - Review

C2 - 38529639

AN - SCOPUS:85189642262

VL - 22

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 4-5

ER -

ID: 389314835